JP2024525492A5 - - Google Patents
Info
- Publication number
- JP2024525492A5 JP2024525492A5 JP2023580800A JP2023580800A JP2024525492A5 JP 2024525492 A5 JP2024525492 A5 JP 2024525492A5 JP 2023580800 A JP2023580800 A JP 2023580800A JP 2023580800 A JP2023580800 A JP 2023580800A JP 2024525492 A5 JP2024525492 A5 JP 2024525492A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- cdr
- amino acid
- acid sequence
- identity
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163216753P | 2021-06-30 | 2021-06-30 | |
| US63/216,753 | 2021-06-30 | ||
| PCT/US2022/035441 WO2023278520A1 (en) | 2021-06-30 | 2022-06-29 | Polypeptides targeting cd70-positive cancers |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024525492A JP2024525492A (ja) | 2024-07-12 |
| JP2024525492A5 true JP2024525492A5 (https=) | 2025-07-07 |
Family
ID=84691552
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023580800A Pending JP2024525492A (ja) | 2021-06-30 | 2022-06-29 | Ｃｄ７０陽性がんを標的とするポリペプチド |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20240269285A1 (https=) |
| EP (1) | EP4363454A4 (https=) |
| JP (1) | JP2024525492A (https=) |
| CN (1) | CN117897405A (https=) |
| AU (1) | AU2022303155A1 (https=) |
| CA (1) | CA3224026A1 (https=) |
| MX (1) | MX2023015101A (https=) |
| WO (1) | WO2023278520A1 (https=) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2024040194A1 (en) | 2022-08-17 | 2024-02-22 | Capstan Therapeutics, Inc. | Conditioning for in vivo immune cell engineering |
| AU2024279278A1 (en) | 2023-05-31 | 2025-12-18 | Capstan Therapeutics, Inc. | Lipid nanoparticle formulations and compositions |
| US20250127728A1 (en) | 2023-10-05 | 2025-04-24 | Capstan Therapeutics, Inc. | Constrained Ionizable Cationic Lipids and Lipid Nanoparticles |
| WO2025076113A1 (en) | 2023-10-05 | 2025-04-10 | Capstan Therapeutics, Inc. | Ionizable cationic lipids with conserved spacing and lipid nanoparticles |
| US20250302763A1 (en) | 2024-02-22 | 2025-10-02 | Capstan Therapeutics, Inc. | Immune engineering amplification |
| WO2025217452A1 (en) | 2024-04-11 | 2025-10-16 | Capstan Therapeutics, Inc. | Constrained ionizable cationic lipids and lipid nanoparticles |
| WO2025217454A2 (en) | 2024-04-11 | 2025-10-16 | Capstan Therapeutics, Inc. | Ionizable cationic lipids and lipid nanoparticles |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20110008766A1 (en) * | 2009-05-01 | 2011-01-13 | Abbott Laboratories | Dual Variable Domain Immunoglobulins and Uses Thereof |
| US8852599B2 (en) * | 2011-05-26 | 2014-10-07 | Bristol-Myers Squibb Company | Immunoconjugates, compositions for making them, and methods of making and use |
| PE20170256A1 (es) * | 2014-01-24 | 2017-04-22 | Ngm Biopharmaceuticals Inc | Proteinas de union y sus metodos de uso |
| TWI785009B (zh) * | 2017-02-14 | 2022-12-01 | 美商凱特製藥公司 | Ｃｄ７０結合分子及使用彼之方法 |
| CN112020518A (zh) * | 2018-02-01 | 2020-12-01 | 辉瑞公司 | 靶向cd70的嵌合抗原受体 |
| AU2020267131A1 (en) * | 2019-05-02 | 2021-11-25 | Revitope Limited | TEAC and ATTAC immunooncology compositions and methods |
| WO2020232292A1 (en) * | 2019-05-15 | 2020-11-19 | Board Of Regents, The University Of Texas System | Methods and compositions for treating non-small cell lung cancer |
-
2022
- 2022-06-29 EP EP22834113.7A patent/EP4363454A4/en active Pending
- 2022-06-29 MX MX2023015101A patent/MX2023015101A/es unknown
- 2022-06-29 JP JP2023580800A patent/JP2024525492A/ja active Pending
- 2022-06-29 WO PCT/US2022/035441 patent/WO2023278520A1/en not_active Ceased
- 2022-06-29 CA CA3224026A patent/CA3224026A1/en active Pending
- 2022-06-29 AU AU2022303155A patent/AU2022303155A1/en active Pending
- 2022-06-29 US US18/567,967 patent/US20240269285A1/en active Pending
- 2022-06-29 CN CN202280055290.2A patent/CN117897405A/zh active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7741732B2 (ja) | Ｂｃｍａを標的とする操作された免疫細胞及びその使用 | |
| JP2024525492A5 (https=) | ||
| US12304935B2 (en) | Immunomodulatory polypeptides and related compositions and methods | |
| CA3094996A1 (en) | Guidance and navigation control proteins and method of making and using thereof | |
| CN116829194A (zh) | 用于工程化细胞疗法的靶向细胞因子构建体 | |
| CA2973529A1 (en) | Cll1-specific multi-chain chimeric antigen receptor | |
| JP2017507917A (ja) | 軟骨魚類由来の抗原認識ドメインを使用したキメラ抗原受容体 | |
| TWI797610B (zh) | 人源化cd19抗體及其應用 | |
| JP2019510786A (ja) | 免疫療法におけるＴＧＦβの阻害 | |
| KR20230155521A (ko) | 면역 세포 기능의 향상 | |
| US20220325241A1 (en) | Immune effector cell for co-expressing chemokine receptor | |
| US20240226154A9 (en) | Car-t constructs comprising a novel cd19 binder combined with il18 and methods of using the same | |
| EP4126016A1 (en) | Augmenting antigen-negative cell death in antigen-targeted immunotherapies | |
| US20230321242A1 (en) | Chimeric antigen receptor (car)-expressing cells recognizing cea | |
| US20240009310A1 (en) | A CHIMERIC ANTIGEN RECEPTOR CONSTRUCT ENCODING A CHECKPOINT INHIBITORY MOLECULE AND AN IMMUNE STIMULATORY CYTOKINE AND CAR-EXPRESSING CELLS RECOGNIZING CD44v6 | |
| HK40110123A (zh) | 靶向bcma的工程化免疫细胞及其用途 | |
| KR20250089551A (ko) | 입양 세포 요법과 표적 면역사이토카인을 조합하여 이용한 암 치료 방법 | |
| HK40062446B (zh) | 靶向bcma的工程化免疫细胞及其用途 | |
| CN117881695A (zh) | 功能强化的新型嵌合抗原受体 | |
| CN121152872A (zh) | 嵌合抗原受体及其使用方法 |